FDA center structure may be ripe for reorganization, Deputy Commissioner Pendergast suggests.
Executive Summary
FDA CENTER STRUCTURE REVISION SHOULD BE CONSIDERED, DEPUTY COMMISSIONER Mary Pendergast suggested during a May 7 Food & Drug Law Institute meeting on tissue product regulation in Washington, D.C. "As technology becomes a seamless web, and not the old chemical drugs, biological drugs and mechanical things, as we realize that there is a seamless web of products out there, we have to continue to work to be a seamless web of an agency," Pendergast said.